CCM
CYTK icon

Consonance Capital Management’s Cytokinetics CYTK Stock Holding History

Consonance Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-3,347,232
Closed -$78.9M – 32
2020
Q2 		$78.9M Sell
3,347,232
-85,000
-2% -$1.59M 4.73% 9
2020
Q1 		$40.5M Buy
+3,432,232
New +$43.8M 3.01% 14

Other funds holding CYTK

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Consonance Capital Management's CYTK Position: Q3 2020 in Review

Consonance Capital Management sold out of Cytokinetics (CYTK) in Q3 2020, closing a stake of 3,347,232 shares — an estimated $78.9M sold.

Consonance Capital Management first reported a position in CYTK in Q1 2020 and held it in 2 quarters. The position peaked at $78.9M in Q2 2020. 181 funds tracked by Wall St. Rank hold CYTK as of Q3 2020.

  • Consonance Capital Management reported no remaining Cytokinetics position as of Q3 2020 after selling out during the quarter.
  • Consonance Capital Management sold 3,347,232 Cytokinetics shares in Q3 2020, an estimated $78.9M.
  • Consonance Capital Management first reported a position in Cytokinetics in Q1 2020 and held it in 2 quarters.
  • Consonance Capital Management's Cytokinetics position peaked at $78.9M in Q2 2020.
  • 181 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2020.

Based on Consonance Capital Management's 13F filing for Q3 2020, filed 16 Nov 2020.